Accelerate Diagnostics Inc (NASDAQ: AXDX)’s stock price has gone decline by -18.92 in comparison to its previous close of 0.15, however, the company has experienced a -78.02% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-05-08 that TUCSON, Ariz., May 8, 2025 /PRNewswire/ — Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (“Accelerate” or the Company”) today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell its assets through a court supervised sale process.
Is It Worth Investing in Accelerate Diagnostics Inc (NASDAQ: AXDX) Right Now?
The stock has a 36-month beta value of 0.25. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AXDX is 15.31M, and at present, short sellers hold a 1.94% of that float. On May 12, 2025, the average trading volume of AXDX was 240.75K shares.
AXDX’s Market Performance
AXDX’s stock has seen a -78.02% decrease for the week, with a -79.31% drop in the past month and a -90.24% fall in the past quarter. The volatility ratio for the week is 41.12%, and the volatility levels for the past 30 days are at 17.81% for Accelerate Diagnostics Inc The simple moving average for the past 20 days is -74.77% for AXDX’s stock, with a -90.94% simple moving average for the past 200 days.
Analysts’ Opinion of AXDX
Many brokerage firms have already submitted their reports for AXDX stocks, with Craig Hallum repeating the rating for AXDX by listing it as a “Hold.” The predicted price for AXDX in the upcoming period, according to Craig Hallum is $5 based on the research report published on March 09, 2022 of the previous year 2022.
Craig Hallum gave a rating of “Buy” to AXDX, setting the target price at $20 in the report published on August 07th of the previous year.
AXDX Trading at -83.75% from the 50-Day Moving Average
After a stumble in the market that brought AXDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.26% of loss for the given period.
Volatility was left at 17.81%, however, over the last 30 days, the volatility rate increased by 41.12%, as shares sank -78.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -88.89% lower at present.
During the last 5 trading sessions, AXDX fell by -78.02%, which changed the moving average for the period of 200-days by -90.40% in comparison to the 20-day moving average, which settled at $0.4755. In addition, Accelerate Diagnostics Inc saw -90.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AXDX starting from Phillips Jack, who sale 25,343 shares at the price of $0.65 back on Apr 04 ’25. After this action, Phillips Jack now owns 191,374 shares of Accelerate Diagnostics Inc, valued at $16,473 using the latest closing price.
Mertz Larry Michael, the Chief Technology Officer of Accelerate Diagnostics Inc, sale 1,523 shares at $0.65 during a trade that took place back on Apr 04 ’25, which means that Mertz Larry Michael is holding 84,803 shares at $990 based on the most recent closing price.
Stock Fundamentals for AXDX
Current profitability levels for the company are sitting at:
- -3.02 for the present operating margin
- 0.23 for the gross margin
The net margin for Accelerate Diagnostics Inc stands at -4.28. The total capital return value is set at 13.35.
Based on Accelerate Diagnostics Inc (AXDX), the company’s capital structure generated 6.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.36. The debt to equity ratio resting at -1.19. The interest coverage ratio of the stock is -2.69.
Currently, EBITDA for the company is -33.57 million with net debt to EBITDA at -1.53. When we switch over and look at the enterprise to sales, we see a ratio of 4.66. The receivables turnover for the company is 5.74for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.71.
Conclusion
To sum up, Accelerate Diagnostics Inc (AXDX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
